The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Pamidronate Reduces Skeletal Morbidity in Women With Advanced Breast Cancer and Lytic Bone Lesions: A Randomized, Placebo-Controlled Trial
Abstract
PURPOSE: To assess whether pamidronate can reduce the frequency of skeletal morbidity in women with lytic bone metastases from breast cancer treated with hormone therapy. PATIENTS AND METHODS: Three hundred seventy-two women with breast cancer who had at least one lytic bone lesion and who were receiving hormonal therapy were randomized to receive 90 mg of pamidronate or placebo as a 2-hour intravenous infusion given in double-blind fashion every 4 weeks for 24 cycles. Patients were evaluated for skeletal complications: pathologic fractures, spinal cord compression, irradiation of or surgery on bone, or hypercalcemia. The skeletal morbidity rate (the ratio of the number of skeletal complications to the time on trial) was the primary efficacy variable. Bone pain, use of analgesics, quality of life, performance status, bone tumor response, and biochemical parameters were also evaluated. RESULTS: One hundred eighty-two patients who received pamidronate and 189 who received placebo were assessable. The skeletal morbidity rate was significantly reduced at 12, 18, and 24 cycles in patients treated with 90 mg of pamidronate (P = .028, .023, and .008, respectively). At 24 cycles, the proportion of patients having had any skeletal complication was 56% in the pamidronate group and 67% in the placebo group (P = .027). The time to the first skeletal complication was longer for patients receiving pamidronate than for those given placebo (P = .049). There was no statistical difference in survival or in objective bone response rate. Pamidronate was well tolerated. CONCLUSION: Treatment with 90 mg of pamidronate as a 2-hour intravenous infusion every 4 weeks in addition to hormonal therapy significantly reduces skeletal morbidity from osteolytic metastases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Beahrs, O. H., & Henson, D. E. (1992) · Medical Entomology and Zoology · Cited by 2,460
Measuring the quality of life of cancer patients
Spitzer, W. O., Dobson, A. J., Hall, J., Chesterman, E., Levi, J., Shepherd, R., Battista, R. N., & Catchlove, B. R. (1981) · Journal of Chronic Diseases · doi:10.1016/0021-9681(81)90058-8 · Cited by 1,528
Bertolini, D. R., Nedwin, G. E., Bringman, T. S., Smith, D. D., & Mundy, G. R. (1986) · Nature · doi:10.1038/319516a0 · Cited by 1,434
Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma
Berenson, J. R., Lichtenstein, A., Porter, L., Dimopoulos, M. A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M. J., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602223340802 · Cited by 1,081
Self-citationHortobagyi, G. N., Theriault, R. L., Porter, L., Blayney, D., Lipton, A., Sinoff, C., Wheeler, H., Simeone, J. F., Seaman, J., Knight, R. D., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612123352401 · Cited by 1,026
Self-citationParfitt, A. M. (1994) · Journal of Cellular Biochemistry · doi:10.1002/jcb.240550303 · Cited by 1,001
Esophagitis Associated with the Use of Alendronate
de Groen, P. C., Lubbe, D. F., Hirsch, L. J., Daifotis, A., Stephenson, W., Freedholm, D., Pryor-Tillotson, S., Seleznick, M. J., Pinkas, H., & Wang, K. K. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351403 · Cited by 764
Paterson, A. H., Powles, T. J., Kanis, J. A., McCloskey, E., Hanson, J., & Ashley, S. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.1.59 · Cited by 557
Nussbaum, S. R., Younger, J., Vandepol, C. J., Gagel, R. F., Zubler, M. A., Chapman, R., Henderson, I. C., & Mallette, L. E. (1993) · The American Journal of Medicine · doi:10.1016/0002-9343(93)90282-t · Cited by 228
Palliative pamidronate treatment in patients with bone metastases from breast cancer.
van Holten-Verzantvoort, A. T., Kroon, H. M., Bijvoet, O. L., Cleton, F. J., Beex, L. V., Blijham, G., Hermans, J., Neijt, J. P., Papapoulos, S. E., & Sleeboom, H. P. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.491 · Cited by 196
Bisphosphonates: A New Class of Drugs in Diseases of Bone and Calcium Metabolism
Fleisch, H. (1989) · Recent Results in Cancer Research · doi:10.1007/978-3-642-83668-8_1 · Cited by 182
INHIBITION OF OSTEOLYTIC BONE LESIONS BY (3-AMINO-1-HYDROXYPROPYLIDENE)-1, 1-BISPHOSPHONATE (A.P.D.)
Van Breukelen, F. J. M., Bijvoet, O., & Van Oosterom, A. T. (1979) · The Lancet · doi:10.1016/s0140-6736(79)91319-9 · Cited by 173
Pamidronate: An unrecognized problem in gastrointestinal tolerability
Lufkin, E. G., Argueta, R., Whitaker, M. D., Cameron, A. L., Wong, V. H., Egan, K. S., O'Fallon, W. M., & Riggs, B. L. (1994) · Osteoporosis International · doi:10.1007/bf01622190 · Cited by 172
Flanagan, A. M., & Chambers, T. J. (1991) · Calcified Tissue International · doi:10.1007/bf02555852 · Cited by 171
Mechanisms of osteolytic bone destruction
Mundy, G. R. (1991) · Bone · doi:10.1016/8756-3282(91)90057-p · Cited by 139
Coleman, R., Woll, P. J., Miles, M., Scrivener, W., & Rubens, R. (1988) · British Journal of Cancer · doi:10.1038/bjc.1988.272 · Cited by 128
Phase II study of tamoxifen: report of 74 patients with stage IV breast cancer.
Lerner, H. J., Band, P. R., Israël, L., & Leung, B. S. (1976) · PubMed · Cited by 108
Bone metastases and breast cancer
Coleman, R. E., & Rubens, R. D. (1985) · Cancer Treatment Reviews · doi:10.1016/0305-7372(85)90008-8 · Cited by 97
Morton, A. R., Cantrill, J. A., Pillai, G. V., McMahon, A., Anderson, D. C., & Howell, A. (1988) · BMJ · doi:10.1136/bmj.297.6651.772 · Cited by 87
Treatment of bone metastases from breast cancer and myeloma with pamidronate.
Thiébaud, D., Leyvraz, S., von Fliedner, V., Perey, L., Cornu, P., Thiébaud, S., & Burckhardt, P. (1991) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(91)90056-j · Cited by 75
Effects of dichloromethylene diphosphonate in women with breast carcinoma metastatic to the skeleton
Siris, E. S., Hyman, G. A., & Canfield, R. E. (1983) · The American Journal of Medicine · doi:10.1016/0002-9343(83)90958-0 · Cited by 73
Oral medroxyprogesterone acetate in the treatment of metastatic breast cancer
Hortobágyi, G. N., Buzdar, A. U., Frye, D. K., Yap, H. Y., Hug, V., Pinnamaneni, K., Fraschini, G., Halvorson, H. C., & Blumenschein, G. R. (1985) · Breast Cancer Research and Treatment · doi:10.1007/bf01806027 · Cited by 47
Use of aminoglutethimide as second-line endocrine therapy in metastatic breast cancer.
Kaye, S. B., Woods, R. L., Fox, R. M., et al. (1982) · PubMed · Cited by 21
Cited by
Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases
Ruggiero, S. L., Mehrotra, B., Rosenberg, T. J., & Engroff, S. L. (2004) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2004.02.004 · Cited by 2,057
Metastatic bone disease: clinical features, pathophysiology and treatment strategies
Coleman, R. E. (2001) · Cancer Treatment Reviews · doi:10.1053/ctrv.2000.0210 · Cited by 1,920
Stopeck, A. T., Lipton, A., Body, J.-J., Steger, G. G., Tonkin, K., de Boer, R. H., Lichinitser, M., Fujiwara, Y., Yardley, D. A., Viniegra, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.7101 · Cited by 1,597
Self-citationBreast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0016 · Cited by 1,584
Rosen, L. S., Gordon, D., Kaminski, M., Howell, A., Belch, A., Mackey, J., Apffelstaedt, J., Hussein, M. A., Coleman, R. E., Reitsma, D. J., et al. (2003) · Cancer · doi:10.1002/cncr.11701 · Cited by 873
Self-citation
Metadata
- Authors
- Theriault, R. L., Lipton, A., Hortobagyi, G. N., Leff, R., Glück, S., Stewart, J. F., Costello, S., Kennedy, I., Simeone, J., Seaman, J. J., Knight, R. D., Mellars, K., Heffernan, M., & Reitsma, D. J.
- Venue
- Journal of Clinical Oncology
- Published
- 1999-03
- Volume
- 17
- Issue
- 3
- Pages
- 846-846
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1768011742
- Cited by
- 604
- References
- 23
- FWCI
- 13.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.